Abstract
Integrin α 5 β 1 plays an important role in developmental angiogenesis, but its role in various types of pathologic neovascularization has not been completely defined. In this study, we found strong upregulation of α 5 β 1 in choroidal neovascularization. Implantation of an osmotic pump delivering 1.5 or 10 µg/hour (~1.8 or 12 mg/kg/day) of JSM6427, a selective α 5 β 1 antagonist, caused significant suppression of choroidal neovascularization; the area of neovascularization was reduced by 33 to 40%. When an osmotic pump delivering 10 µg/hour of JSM6427 was implanted 7 days after rupture of Bruch's membrane, there was TUNEL staining in vascular cells within the neovascularization and significant regression of the neovascularization over the next week. JSM6427 also induced apoptosis of cultured vascular endothelial cells. Fibronectin stimulates phosphorylation of extracellular signal regulated kinase (ERK) in α 5 β 1 -expressing cells and this is blocked by JSM6427. These data suggest that α 5 β 1 plays a role in the development and maintenance of choroidal neovascularization and provides a target for therapeutic intervention.
Introduction
Vascular endothelial cells participating in angiogenesis get signals from several sources. Surrounding tissue that senses the need for increased blood (oxygen) delivery is an important source of soluble stimulators. In hypoxic tissue, the transcription factor, hypoxia inducible factor-1 (HIF-1) is stabilized, resulting in upregulation of several genes (Manalo et al., 2005) . Vascular endothelial growth factor (VEGF) is an important hypoxia-regulated soluble signal produced by surrounding tissue that promotes neovascularization. Things other than hypoxia, such as cytokines, also up-regulate VEGF, and in many instances this appears to be through HIF-1 or HIF-2 (Bardos et al., 2004; Haddad and Harb, 2005) . While other soluble signals undoubtedly play a role, it is clear that inhibition of VEGF is a useful strategy for treatment of neovascular diseases (Ribatti, 2005) .
Another source of signals is the extracellular matrix (ECM). The ECM seems capable of providing both stabilizing signals that suppress neovascularization and stimulatory signals (Sottile, 2004) . Integrins are cell surface receptors that mediate signaling from the ECM and one way that signaling from ECM is modulated is by alterations in the integrin population on the cell surface. Therefore, it is important to determine in any given situation, which integrins mediate stimulation of neovascularization and which seem to suppress it.
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Integrins α v β 3 and α v β 5 are up-regulated on endothelial cells participating in several types of neovascularization, including tumor vessels and retinal neovascularization (Brooks et al., 1994a; Brooks et al., 1994b; Luna et al., 1996) .
Antagonists of α v β 3 and α v β 5 suppress tumor neovascularization and retinal neovascularization (Hammes et al., 1996; Luna et al., 1996) . However, the same antagonists of α v β 3 and α v β 5 that suppress retinal neovascularization, have no identifiable suppressive effect on choroidal neovascularization in mice (unpublished data). Gene knockout studies have shown that deletion of α v , β 3 , and/or β 5 fails to block developmental angiogenesis and in some cases may enhance angiogenesis (Hynes, 2002) . Therefore, it appears that the role of integrins in neovascularization in one situation does not guarantee participation in a different vascular bed and different disease process.
Integrin α 5 β 1 is also up-regulated on activated endothelial cells and tumor blood vessels (Collo and Pepper, 1999; Kim et al., 2000; Magnussen et al., 2005; Parsons-Wingerter et al., 2005) . Antagonists of α 5 β 1 suppress angiogenesis on chick chorioallantoic membrane induced by FGF2, tumor necrosis factor-α (TNF-α) or interleukin-8 (IL-8) and in murine tumor models (Kim et al., 2000; Magnussen et al., 2005; Stoeltzing et al., 2003) . Integrin α 5 β 1 also plays a critical role in developmental angiogenesis (Hynes, 2002; Yang et al., 1993) . During vascularization of the central nervous system, angiogenic sprouts express high levels of α 5 β 1 and it is markedly reduced as the vessels mature (Milner and Campbell, 2002) . Thus, α 5 β 1 appears to promote angiogenesis in multiple settings, but as noted above, one cannot assume that it is proangiogenic in all tissues and pathologies. In this study, we have explored the role of α 5 β 1 in choroidal neovascularization, the most common cause of severe vision loss in elderly Americans (Klein et al., 1993) .
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Materials and Methods

Mouse model of choroidal neovascularization
Mice were treated in accordance with the Association for Research in Vision and Ophthalmology guidelines for the use of animals in research.
Choroidal neovascularization was induced by laser photocoagulation-induced rupture of Bruch's membrane as previously described (Tobe et al., 1998) .
Briefly, 5 to 6 week old female C57BL/6J mice were anesthetized with ketamine hydrochloride (100 mg/kg body weight), and pupils were dilated with 1% tropicamide. Three burns of 532 nm diode laser photocoagulation (75 µm spot size, 0.1 seconds duration, 120 mW) were delivered to each retina with the slit lamp delivery system of an OcuLight GL diode laser (Iridex, Mountain View, CA) using a handheld cover slip as a contact lens to view the retina. Burns were performed in the 9, 12, and 3 o'clock positions of the posterior pole of the retina.
Production of a bubble at the time of laser, which indicates rupture of Bruch's membrane, is an important factor in obtaining choroidal neovascularization, and therefore, only burns in which a bubble was produced were included in the study.
Immunohistochemistry and histochemistry
Two weeks after rupture of Bruch's membrane, mice were euthanized and eyes were removed and fixed for 30 minutes in 0.1 M phosphate buffer, pH 7.6 containing 4% paraformaldehyde and 5% sucrose. After 30 minutes, corneas and lenses were removed and then fixation was continued for another hour.
This article has not been copyedited and formatted. The final version may differ from this version. beneath the skin of the back and the following day the mice had laser-induced rupture of Bruch's membrane at 3 locations in each eye. After 14 days, the mice were perfused with 1 ml of PBS containing 50 mg/ml of fluorescein-labeled dextran (2 x 10 6 average molecular weight, Sigma-Aldrich, St. Louis, MO) and choroidal flat mounts were prepared as previously described. Briefly, eyes were removed and fixed for 1 hour in 10% phosphate-buffered formalin. The cornea, lens, and retina were removed and four radial cuts were made in the eyecup allowing it to be flat mounted in aqueous mounting medium. Flat mounts were examined by fluorescence microscopy and images were digitized using a threeThis article has not been copyedited and formatted. The final version may differ from this version. To assess the effect of JSM6427 on established choroidal neovascularization, mice had rupture of Bruch's membrane at 3 locations in each eye and after 7 days, 9 mice were perfused with fluorescein-labeled dextran and the baseline area of neovascularization at each rupture site was measured. The remaining mice had implantation of osmotic mini-pumps containing 20 mg/ml of JSM6427 in 100 mM Na phosphate buffer, 50 mM NaCl, pH 7.4 or vehicle alone.
At 7 days after implantation some mice were euthanized for terminal deoxynucleotidyl transferase-mediated dUTP-FITC nick-end labeling (TUNEL).
The remainder of the mice was perfused with fluorescein-labeled dextran 7 days after implantation and the area of choroidal neovascularization at rupture sites was measured.
Intravitreous injections of JSM6427
Mice had rupture of Bruch's membrane at 3 locations in each eye and were given an intravitreous injection of 1 µl of vehicle (PBS or 100 mM phosphate buffer, 50 mM NaCl, pH 7.4) containing of 3 or 20 µg of JSM6427 in one eye and 1 µl of vehicle alone in the other eye on days 0 and 7. For an additional control, some mice did not receive any injection. On day 14 the mice were perfused with fluorescein-labeled dextran and the area of choroidal neovascularization at Bruch's membrane rupture sites was measured.
Identification of apoptotic cells in vivo by TUNEL
Eyes were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer and frozen in OCT. Ten µm serial sections were cut through each rupture site.
Sections were fixed with 1% paraformaldehyde for 10 minutes at room temperature and TUNEL was done with the ApopTag Red kit (S7165, Chemicon)
according to the manufacturer's instructions. The sections were also histochemically stained with GSA as described above. Slides were also stained with DAPI and mounted in aqueous mounting medium.
Statistical analysis
Data were analyzed using linear mixed model accounting for possible correlations in measurements from the same mice. Dunnett's adjustment was made for multiple comparisons.
Solid phase binding assay
The inhibiting activity and integrin selectivity of the integrin inhibitor was Europe, Germany). The integrin antibodies were purchased from Pharmingen, BD Bioscience Europe (α V β 3 ) and Sigma (anti-human-Fc-HRP antibody conjugate and anti-mouse-HRP conjugate).
The detection of HRP was performed using HRP substrate solution 3.3.5.5'-tetramethylethylenediamine (TMB, Seramun, Germany) and 1M H 2 SO 4
for stoping the reaction. The developed color was measured at 450nm.
α 5 β 1 :Nunc-Immuno maxisorp plates (Nalge Nunc Europe Ltd) were coated over night at 4°C with fibronectin (0.25 µg/ml) in 15 mM Na 2 CO 3 , 35 mM NaHCO 3 , pH9.6. All subsequent washing and binding were performed in 25 mM Tris, pH7.6, 150 mM NaCl, 1 mM MnCl 2 , 1 mg/ml BSA. The plates were blocked with 3 % BSA in PBS 0.1 % Tween20 for 1 hour at room temperature. Soluble integrin α 5 β 1 (0.5 µg/ml) and a serial dilution of integrin inhibitor were incubated in the coated wells for one hour at room temperature. The detection antibody (antihuman-Fc-HRP antibody conjugate) was then applied for 1 hour at room temperature and the binding visualized as described above. For the α V β 3 assay, plates were coated with vitronectin (1 µg/ml) and blocked as described for α 5 β 1 .
Soluble α V β 3 (1 µg/ml) was incubated with a serial dilution of integrin inhibitor for one hour at room temperature. Primary (anti-α V β 3 ) and secondary antibody (antimouse-HRP conjugate) were applied for 1 hour at RT and the binding visualized as described above. All IC 50 measurements were performed at least 30 times.
Identification of apoptotic cells in vitro by TUNEL and fluorescent activated cell sorting (FACS)
This article has not been copyedited and formatted. The final version may differ from this version. The integrin inhibitor JSM6427 is an antagonist of binding to integrin α 5 β 1 and is at least 1200-fold less potent in the inhibition of binding to α V β 3 , the integrin that is most closely related to α 5 β 1 in structure ( against other integrins such as α V β 5 and α IIb β 3 is significantly higher, 3,700-fold or > 100,000-fold, respectively (data not shown).
Subcutaneous delivery of JSM6427 suppresses choroidal neovascularization
Osmotic minipumps (Figure 2A ) that release 1.5 or 10 µg per hour of JSM6427 or vehicle alone were implanted beneath the skin on the backs of mice ( Figure 2B ) and the following day Bruch's membrane was ruptured in 3 locations in each eye. Fourteen days after rupture of Bruch's membrane, the size of choroidal neovascularization lesions at rupture sites in mice that received 1.5 or 10 µg per hour of JSM6427 ( Figure 2C and F) appeared smaller than corresponding controls that received infusion of vehicle ( Figure 2D and G).
Measurement of the size of the lesions by image analysis confirmed that for both infusion rates of JSM6427, 1.5 ( Figure 2E ) and 10 µg per hour ( Figure 2H ), choroidal neovascularization lesions were significantly smaller than corresponding vehicle controls by about 33% or 40%, respectively.
Subcutaneous delivery of JSM6427 causes regression of established choroidal neovascularization
Mice had laser-induced rupture of Bruch's membrane and after 7 days some mice were used to measure the baseline amount of choroidal neovascularization ( Figure 3A) . The remainder of the mice had implantation of an osmotic minipump that released 10 µg/hour of JSM6427 or vehicle. After 7
This article has not been copyedited and formatted. The final version may differ from this version. days of treatment, the mice infused with JSM6427 had small choroidal neovascularization lesions at Bruch's membrane rupture sites ( Figure 3B ), while mice infused with vehicle had lesions that appeared larger ( Figure 3C ). TUNEL showed labeling within the outer nuclear layer (ONL) of the retina overlying choroidal neovascularization in day 7 baseline eyes ( Figure 3D ). This is likely to be a consequence of the laser photocoagulation that was used to induce rupture of Bruch's membrane, although it is possible that the presence of choroidal neovascularization is damaging to the overlying retina due to interference with transmission of oxygen from the choroid, interference with transmission of survival signals from the retinal pigmented epithelium, or some other reason. At 14 days after rupture of Bruch's membrane, mice infused with JSM6427 for the previous 7 days ( Figure 3E ) and those infused with vehicle ( Figure 3F ) showed apoptosis in the retina overlying choroidal neovascularization, but only the mice infused with JSM6427 showed apoptosis of vascular cells within the choroidal neovascularization as expected for the proposed mechanism of action and confirmed with in vitro apoptosis assays (see below, Figure 4 ). Figure 3G shows the boxed region in Figure 3E at high magnification providing better visualization of 2 yellow cells (arrows) due to colocalization of GSA and ApopTag red.
Measurement of the size of choroidal neovascularization lesions by image
analysis showed that mice infused with JSM6427 had significantly smaller lesions than those seen at baseline or those seen in mice infused with vehicle ( Figure 3H ). This indicates that continuous systemic infusion of JSM6427 causes regression of choroidal neovascularization.
JSM6427 causes apoptosis of vascular endothelial cells in vitro
HUVEC cells were grown in fibronectin-coated wells for 48 hours in serum-free medium containing various concentrations of JSM6427.
Campthotecin, a strong inducer of apoptosis, was used as a positive control.
JSM6427 caused a dose-dependent increase in the percentage of TUNELpositive cells in cultures ranging from 44% for those incubated with 50 µM to 6%
for those incubated in 100 nM (Figure 4) . In cultures incubated in serum-free medium, 5% of cells were TUNEL-positive and 82% of cells were labelled in cultures incubated with 10 µM campthotecin. These data show that JSM6427
induces apoptosis of vascular endothelial cells.
JSM6427 reduces fibronectin-induced phosphorylation of ERK
The mechanism by which ECM components generate survival signals than those plated on poly-L-lysine or those kept in suspension ( Figure 5A ). Preincubation with JSM6427 prior to plating on fibronectin caused a dose-dependent reduction in the amount of phosphorylated ERK in the cultures. Quantification of the signal for phosphorylated ERK normalized to the total amount of ERK showed that pre-incubation with 10 µM JSM6427 completely eliminated the fibronectin-induced stimulation of ERK phosphorylation ( Figure 5B ) and the IC 50 was 0.23 µM ( Figure 5C ).
Two intravitreous injections of JSM6427 did not cause significant suppression of choroidal neovascularization
To explore the feasibility of local delivery of JSM6427, mice had laser- Despite the apparent safety of sustained systemic administration of JSM6427, local administration has the theoretical benefit of limiting exposure to the rest of the body and reducing the total amount of JSM6427 that is required for treatment. Two intravitreous injections of JSM6427 over the course of 2 weeks failed to suppress choroidal neovascularization. A possible explanation is that sustained exposure of JSM6427 to endothelial cells in choroidal neovascular lesions is necessary to perturb survival signals and even brief lapses in blockade of α 5 β 1 signaling may be sufficient to prevent apoptosis. In the future, it will be worthwhile to test this hypothesis by assessing the effect of sustained local delivery of JSM6427.
This article has not been copyedited and formatted. The final version may differ from this version. Choroidal neovascularization occurs in diseases of the retinal pigmented epithelium/Bruch's membrane complex. The most common of these is agerelated macular degeneration (AMD), which is the most prevalent cause of severe vision loss in patients over the age of 60 in developed countries (Klein et al., 1993) . Studies in animal models have demonstrated that VEGF is an important stimulus and that VEGF antagonists suppress the neovascularization (Kryzstolik et al., 2002; Kwak et al., 2000; Saishin et al., 2003) . The role of VEGF in patients with neovascular AMD has now been confirmed in a clinical trial demonstrating that multiple intravitreous injections of pegaptanib, an aptamer that binds VEGF, slows the rate of visual loss (Gragoudas et al., 2004) .
This is a useful start to pharmacotherapy for choroidal neovascularization, but further improvements are needed. Regression of choroidal neovascularization is not achieved in patients treated with pegaptanib; the size of lesions continued to increase over the course of a year, although at a slower rate than that seen in patients that did not receive pegaptanib. Antagonism of VEGF appears to reduce excessive permeability and slows growth, but does not cause involution of choroidal neovascularization. VEGF provides some survival signals to newly developed endothelial cells (Alon et al., 1995) , but survival signals from the extracellular matrix may be sufficient to allow continued growth of choroidal neovascular lesions, although at a slower rate. Combination treatment using JSM6427 with a VEGF antagonist may be extremely useful since perturbation of at least one source of matrix-derived survival signaling along with elimination of C. The IC50 value was calculated using XLFit software. All of these results were replicated in an independent experiment. at ASPET Journals on November 7, 2017 molpharm.aspetjournals.org Downloaded from
